Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients

Author(s): Paula Lana de Miranda Drummond*, Roberta Márcia Marques dos Santos, Lívia Pena Silveira, Jéssica Soares Malta, Adriano Max Moreira Reis, Naiane Lima Costa, Roberta Oliveira de Paula e Silva, Evandro Maranhão Fagundes and Cristiane Aparecida Menezes de Pádua

Volume 19, Issue 3, 2024

Published on: 12 September, 2023

Page: [356 - 367] Pages: 12

DOI: 10.2174/1574886318666230817162424

Price: $65

conference banner
Abstract

Background: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapyinduced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health- Related Quality of Life (HRQoL) and activities of daily living (ADL).

Objective: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL.

Methods: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables.

Results: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL.

Conclusion: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities.

« Previous Next »
Graphical Abstract

[1]
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014; 32(6): 587-600.
[http://dx.doi.org/10.1200/JCO.2013.48.7934] [PMID: 24419113]
[2]
Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol 2018; 93(8): 1091-110.
[http://dx.doi.org/10.1002/ajh.25117] [PMID: 30400719]
[3]
Institute for Health Metrics and Evaluation (IHME). GBD Compare 2015. Available from https://vizhub.healthdata.org/gbd-compare
[4]
Ministério da Saúde Secretaria de Atenção à Saúde Portaria no 708, de 6 de agosto Aprova as Diretrizes Diagnósticas e Terapêuticas do Mieloma Múltiplo 2015. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/sas/2015/prt0708_06_08_2015.html
[5]
Koeppen S. Treatment of multiple myeloma: Thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy. Oncol Res Treat 2014; 37(9): 506-13.
[http://dx.doi.org/10.1159/000365534] [PMID: 25231692]
[6]
Beijers AJM, Vreugdenhil G, Oerlemans S, et al. Chemotherapy-induced neuropathy in multiple myeloma: Influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer 2016; 24(6): 2411-20.
[http://dx.doi.org/10.1007/s00520-015-3032-y] [PMID: 26634561]
[7]
Oh PJ, Lee JR, Kim SK, Kim JH. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study. Eur J Oncol Nurs 2019; 2020: 44.
[PMID: 31751847]
[8]
Kerckhove N, Collin A, Condé S, et al. Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology Bull Cancer 2018; 105(11): 1020-32.
[http://dx.doi.org/10.1016/j.bulcan.2018.07.009] [PMID: 30244980]
[9]
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019; 20(6): 1451.
[http://dx.doi.org/10.3390/ijms20061451] [PMID: 30909387]
[10]
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017; 81(6): 772-81.
[http://dx.doi.org/10.1002/ana.24951] [PMID: 28486769]
[11]
Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K. Complications of multiple myeloma therapy, part 1: Risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw 2010; 8 (Suppl. 1): S-4-S-12.
[http://dx.doi.org/10.6004/jnccn.2010.0115] [PMID: 20141673]
[12]
Li T, Timmins HC, King T, Kiernan MC, Goldstein D, Park SB. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. Hematol Oncol 2020; 38(3): 229-43.
[http://dx.doi.org/10.1002/hon.2706] [PMID: 31873944]
[13]
Li T, Timmins HC, Lazarus HM, Park SB. Peripheral neuropathy in hematologic malignancies – Past, present and future. Blood Rev 2020; 43: 100653.
[http://dx.doi.org/10.1016/j.blre.2020.100653] [PMID: 31983507]
[14]
Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O’Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59(12): 1872-5.
[http://dx.doi.org/10.1212/01.WNL.0000037480.59194.85] [PMID: 12499476]
[15]
Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Living with advanced but stable multiple myeloma: A study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage 2013; 46(5): 671-80.
[http://dx.doi.org/10.1016/j.jpainsymman.2012.11.003] [PMID: 23535325]
[16]
Hsu HT, Wu LM, Lin PC, Juan CH, Huang YY, Chou PL. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. In: Medicine (Baltimore). 2020; 99: p. (6)e19029.
[http://dx.doi.org/10.1097/MD.0000000000019029]
[17]
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-56.
[http://dx.doi.org/10.1097/00000421-198212000-00014] [PMID: 7165009]
[18]
Ramos LR, Tavares NUL, Bertoldi AD, et al. Polypharmacy and Polymorbidity in Older Adults in Brazil: A public health challenge. Rev Saude Publica 2016; 50 (Suppl. 2): 9s.
[http://dx.doi.org/10.1590/s1518-8787.2016050006145] [PMID: 27982377]
[19]
da Silva Simão DA, Teixeira AL, Souza RS, de Paula Lima EDR. Evaluation of the Semmes–Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy. Support Care Cancer 2014; 22(10): 2767-73.
[http://dx.doi.org/10.1007/s00520-014-2275-3] [PMID: 24811218]
[20]
Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005; 5(1): 116.
[http://dx.doi.org/10.1186/1471-2407-5-116] [PMID: 16168057]
[21]
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available From: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
[22]
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365-76.
[http://dx.doi.org/10.1093/jnci/85.5.365] [PMID: 8433390]
[23]
Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007; 43(11): 1670-8.
[http://dx.doi.org/10.1016/j.ejca.2007.04.022] [PMID: 17574838]
[24]
Paiva CE, Carneseca EC, Barroso EM, et al. Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status. Support Care Cancer 2014; 22(8): 2151-60.
[http://dx.doi.org/10.1007/s00520-014-2206-3] [PMID: 24652051]
[25]
Etto LY, Morelli VM, Silva VC, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics (São Paulo) 2011; 66(11): 1855-9.
[PMID: 22086513]
[26]
Malta JS, Silveira LP, Drummond PLM, et al. Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma. Curr Med Res Opin 2021; 37(7): 1163-9.
[http://dx.doi.org/10.1080/03007995.2021.1929136] [PMID: 33979261]
[27]
Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual. 2001. Available From: https://abdn.pure.elsevier.com/en/publications/eortc-qlq-c30-scoring-manual
[28]
Bendel RB, Afifi AA. Comparison of stopping rules in forward “stepwise” regression. J Am Stat Assoc 1977; 72(357): 46.
[29]
Fallon MT, Colvin L. Neuropathic pain in cancer. Br J Anaesth 2013; 111(1): 105-11.
[http://dx.doi.org/10.1093/bja/aet208] [PMID: 23794652]
[30]
Moreira MMC, Rodrigues AB, Oliveira PP, et al. Neuropatia periférica em pessoas com mieloma múltiplo. Acta Paul Enferm 2018; 31(4): 439-45.
[http://dx.doi.org/10.1590/1982-0194201800061]
[31]
van Grootheest AC, de Jong-van den Berg LTW. The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm 2005; 1(1): 126-33.
[http://dx.doi.org/10.1016/j.sapharm.2004.12.009] [PMID: 17138470]
[32]
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer 2014; 22(8): 2261-9.
[http://dx.doi.org/10.1007/s00520-014-2255-7] [PMID: 24789421]
[33]
Selvy M, Kerckhove N, Pereira B, et al. Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: A Single Center Cross-Sectional Study. Front Pharmacol 2021; 12: 637593.
[http://dx.doi.org/10.3389/fphar.2021.637593] [PMID: 33967771]
[34]
Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol 2019; 33: 2058738419838383.
[http://dx.doi.org/10.1177/2058738419838383] [PMID: 30900486]
[35]
Wang M, Pei Z, Molassiotis A. Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review. Eur J Oncol Nurs 2022; 58: 102134.
[http://dx.doi.org/10.1016/j.ejon.2022.102134] [PMID: 35421796]
[36]
Chow R, Novosel M, So OW, et al. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): Systematic review and meta-analysis. BMJ Support Palliat Care 2023; 13(1): 27-34.
[http://dx.doi.org/10.1136/spcare-2022-003815] [PMID: 36194493]
[37]
Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26(4): 595-608.
[http://dx.doi.org/10.1038/leu.2011.346] [PMID: 22193964]
[38]
Angus J, Cumpston A, Veltri L, Ross KG, Wen S, Dillaman M. Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients. Support Care Cancer 2021; 29(12): 7925-30.
[http://dx.doi.org/10.1007/s00520-021-06385-5] [PMID: 34191128]
[39]
Janssen-Cilag International NV ANNEX I Summary of product characteristics 2020. Avaialble From https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf
[40]
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapyinduced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 2012; 82(1): 51-77.
[http://dx.doi.org/10.1016/j.critrevonc.2011.04.012] [PMID: 21908200]
[41]
Sweiss K, Calip GS, Wirth S, Rondelli D, Patel P. Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician–pharmacist clinic. J Oncol Pharm Pract 2020; 26(3): 536-42.
[http://dx.doi.org/10.1177/1078155219851550] [PMID: 31189419]
[42]
Umıt EG, Baysal M, Bas V, Asker I, Kırkızlar O, Demır AM. Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy. J Oncol Pharm Pract 2020; 26(1): 43-50.
[http://dx.doi.org/10.1177/1078155219835303] [PMID: 30890065]
[43]
Machado TRL, Menezes de Pádua CA, Drummond PLM, et al. Use of fall risk-increasing drugs in older adults with multiple myeloma: A cross-sectional study. J Geriatr Oncol 2022; 13(4): 493-8.
[http://dx.doi.org/10.1016/j.jgo.2022.01.007] [PMID: 35086797]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy